NASDAQ · BMRN
Healthcare · Biotechnology
$58.51
Up+$1.02 (+1.77%)
Updated Nov 2, 2026, 3:06 AM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · BMRN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
BMRN closed at $58.51 after 20 trading sessions, up 1.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $58.40 | $59.37 | $57.86 | $58.51 | 2.27M |
| Oct 29, 2026 | $56.58 | $57.506 | $56.29 | $57.49 | 2.62M |
| Oct 28, 2026 | $55.18 | $56.175 | $54.85 | $56.00 | 2M |
| Oct 27, 2026 | $55.83 | $56.09 | $55.0476 | $55.35 | 2.46M |
| Oct 26, 2026 | $56.50 | $56.89 | $55.34 | $55.75 | 2.36M |
| Oct 23, 2026 | $56.68 | $56.81 | $55.24 | $55.95 | 1.68M |
| Oct 22, 2026 | $55.40 | $56.91 | $55.02 | $56.63 | 2.4M |
| Oct 21, 2026 | $56.40 | $57.00 | $54.91 | $55.21 | 2.51M |
| Oct 20, 2026 | $55.08 | $56.48 | $54.95 | $56.44 | 3.47M |
| Oct 19, 2026 | $54.78 | $55.1196 | $54.075 | $54.67 | 3M |
| Oct 16, 2026 | $56.32 | $56.53 | $54.44 | $54.68 | 2.63M |
| Oct 15, 2026 | $56.45 | $57.59 | $55.955 | $56.05 | 2.92M |
| Oct 14, 2026 | $54.75 | $55.56 | $54.46 | $55.14 | 1.85M |
| Oct 13, 2026 | $55.30 | $55.655 | $53.93 | $54.38 | 2.66M |
| Oct 12, 2026 | $55.56 | $55.96 | $54.90 | $55.39 | 2.37M |
| Oct 9, 2026 | $54.80 | $55.975 | $54.48 | $54.795 | 2.15M |
| Oct 8, 2026 | $54.95 | $54.97 | $53.899 | $54.89 | 3.1M |
| Oct 7, 2026 | $56.05 | $56.60 | $54.76 | $55.20 | 2.08M |
| Oct 6, 2026 | $57.54 | $57.875 | $55.76 | $56.22 | 3.72M |
| Oct 5, 2026 | $57.11 | $58.11 | $56.82 | $57.54 | 2.41M |
The latest Smart Investors Daily articles mentioning BMRN.
Company
Market Activity
Research & News
BMRN research
Company profile and research snapshot.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | Overweight | — |
| Oct 20, 2026 | JP Morgan | Overweight | — |
| Oct 20, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 14, 2026 | Barclays | Overweight | — |
| Sep 10, 2026 | HC Wainwright & Co. | Neutral | — |
Generated Nov 1, 2026, 9:14 PM
BioMarin Pharmaceutical gained 1.77% today as the biotech sector showed modest positive momentum, with investor attention turning to the company's strategic licensing activities in rare disease treatments. Recent deal-making activity involving BioMarin's Fabry disease drug candidate has attracted market interest, suggesting continued progress in its pipeline expansion despite a generally slow week for biotech M&A.
Bottom line: BioMarin's modest gain today reflects steady progress on its Fabry disease drug licensing initiative, though the lack of major catalysts suggests investors should watch for clinical trial data or partnership announcements to validate longer-term upside. The company's strategic positioning in rare diseases is encouraging, but investors should monitor pipeline execution and near-term milestones to confirm whether current valuation gains have sustainable fundamentals behind them.
Yahoo · Oct 31, 2026
Is ANAB a good stock to buy? We came across a bullish thesis on AnaptysBio, Inc. on TripleS Special Situations’s Substack. Since the thesis was published on June 15th, ANAB shares have pulled back as uncertainty over its GSK dispute and scrutiny of earnings boosted by a one-time tax benefit weighed on sentiment, creating a near-term hurdle […]
Yahoo · Oct 31, 2026
U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.
Yahoo · Oct 29, 2026
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease.
Benzinga · Oct 29, 2026
HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential to be the first
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BMRN.
